Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6010 + SG001 + capecitabine or 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- CSPC Megalith Biopharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
SYS6010 + SG001 + capecitabine or 5-fluorouracil is a combination therapy developed by CSPC Megalith Biopharmaceutical for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC). The regimen consists of SYS6010, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) with a Dxd analogue payload (JS1) and a cleavable tetrapeptide linker; SG001 (enlonstobart), a recombinant humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; and a fluoropyrimidine-based chemotherapy (either oral capecitabine or intravenous 5-fluorouracil). This multi-modal approach combines targeted cytotoxicity, immune checkpoint blockade, and antimetabolite chemotherapy to improve outcomes in patients with EGFR-expressing squamous cell carcinomas. The combination is currently being evaluated in a Phase 2/3 clinical study.
- Other names
- Enlonstobart5-fluorouracil5-FUCapecitabine
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on SYS6010 + SG001 + capecitabine or 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6010 + SG001 + capecitabine or 5-fluorouracil.